Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below 50 Day Moving Average - Here's Why

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s share price crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $11.49 and traded as low as $11.07. Astria Therapeutics shares last traded at $11.75, with a volume of 213,048 shares changing hands.

Wall Street Analysts Forecast Growth

ATXS has been the subject of several recent research reports. TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a "buy" rating and a $35.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Friday, September 27th. Wedbush reissued an "outperform" rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI raised shares of Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. Finally, Oppenheimer increased their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Astria Therapeutics currently has an average rating of "Buy" and an average price target of $25.20.

Astria Therapeutics Trading Down 4.1 %

The company has a market cap of $618.87 million, a price-to-earnings ratio of -4.86 and a beta of 0.71. The firm's 50-day moving average price is $11.52 and its 200 day moving average price is $10.47.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Analysts forecast that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Astria Therapeutics

Large investors have recently modified their holdings of the stock. Quest Partners LLC grew its position in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after buying an additional 3,112 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 2,861 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Astria Therapeutics in the 3rd quarter worth $155,000. Hsbc Holdings PLC bought a new position in shares of Astria Therapeutics in the 2nd quarter worth $171,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Astria Therapeutics in the 1st quarter worth $200,000. Institutional investors and hedge funds own 98.98% of the company's stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.